The 10-day moving average for EDAP crossed bearishly below the 50-day moving average on June 13, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where EDAP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
EDAP moved below its 50-day moving average on June 01, 2022 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDAP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for EDAP entered a downward trend on June 24, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on June 28, 2022. You may want to consider a long position or call options on EDAP as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for EDAP just turned positive on June 24, 2022. Looking at past instances where EDAP's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDAP advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .
EDAP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDAP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.165) is normal, around the industry mean (6.885). EDAP has a moderately high P/E Ratio (344.828) as compared to the industry average of (92.096). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.201). Dividend Yield (0.000) settles around the average of (0.022) among similar stocks. P/S Ratio (4.505) is also within normal values, averaging (79.458).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of minimally invasive medical devices for urological diseases
A.I.dvisor tells us that EDAP and SIEN have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EDAP and SIEN's prices will move in lockstep.
|SIEN - EDAP|
|SENS - EDAP|
|ISR - EDAP|
|DCTH - EDAP|
|SINT - EDAP|